3billion Q1: Revenue up 67.8% YoY, net loss persists; post-period 30B won capital raising
Q1 2026 consolidated revenue 3.36B won (up 67.8% YoY from 2.0B), operating loss 1.66B won, net loss 1.47B won (improved from 1.71B loss in prior year Q1).
Post-period on April 23, board resolved to raise total 30B won: 17.5B won convertible preferred shares and 12.5B won convertible bonds (payment expected May 13).
Cash and cash equivalents 6.29B won, short-term financial instruments 8.0B won, total liquidity ~14.29B won (down from 18.14B at year-end).
Allowance for doubtful accounts on trade receivables and contract assets increased to 91.9M won (from 34.1M at year-end), with bad debt expense of 57.8M won (vs 21.1M in prior Q1).
Overseas revenue share 70.6%, Full Service accounts for 84.7% of revenue; export growth continues YoY.
R&D expenses 0.99B won (29% of revenue), holding 44 patents. Expanding business through AI drug discovery platform and US subsidiary.
Debt ratio 25.9%, no borrowings, lease liabilities 3.14B won. Consolidated equity 22.47B won.